CERO THERAPEUTICS HOLDINGS, INC.
Close on Oct 19, 2026
- Market cap
- $253.05K
- P/E (TTM)
- –
- Dividend yield
- 172833.33%
About Cero Therapeutics
Biological Products, (No Diagnostic Substances), SIC 2836
CERo Therapeutics Holdings, Inc. is a clinical-stage biotechnology company focused on developing genetically engineered cellular immunotherapies for cancer treatment. The company designs Chimeric Engulfment Receptor T cell therapies, known as CER-T cells, which integrate characteristics of innate and adaptive immune responses to target and eliminate cancer cells. Its primary product candidate in development is CER-1236. Because its candidate therapies remain in early clinical or preclinical stages, the company has not yet commercialized any therapies, meaning its potential future customers will consist of cancer patients and healthcare providers upon regulatory approval.
The company operates in the United States and has no commercial products or physical retail stores. It conducts its research and clinical development through third-party contract development and manufacturing organizations, contract research organizations, and suppliers. CERo Therapeutics maintains its principal executive offices and headquarters in South San Francisco, California.
Summary of the business section of Cero Therapeutics's latest annual report, written by StockData.
Company profile
Company
- Legal name
- CERO THERAPEUTICS HOLDINGS, INC.
- Headquarters
- South San Francisco, CA
- Address
- 201 Haskins Way, Suite 230 94080
- Phone
- (650) 407-2376
- Website
- cero.bio
- Employees
- 8, Dec 31, 2025
- Industry
- Biological Products, (No Diagnostic Substances)
- Incorporated in
- Delaware
- Fiscal year ends
- December 31
- Auditor
- Salberg & Company, P.A., Boca Raton, Florida
Stock & identifiers
- Ticker
- CERO
- Other tickers
- CEROW
- Exchange
- OTC
- IPO date
- Oct 8, 2021
- Shares outstanding
- 72M, Aug 13, 2026
- Public float
- $11.24M, Jun 30, 2025
- Filer category
- <br>Emerging growth company
- Stock splits
- 1-for-20 reverse, Aug 22, 2025; 1-for-20 reverse, Jun 13, 2025; 1-for-100 reverse, Apr 15, 2025; 1-for-100 reverse, Jan 8, 2025
- SEC CIK
- 1870404
- CUSIP
- 71902K402
- ISIN
- US71902K4022
- EIN
- 87-1088814
Executives and directors
Officers and directors who filed ownership reports (Forms 3, 4, 5) in the last two years
| Name | Position | Shares owned |
|---|---|---|
| Christopher B. Ehrlich | Chairman and CEO, Director | 11,091,654 |
| Kristen Pierce | Chief Development Officer | – |
| Andrew Albert Kucharchuk | Chief Financial Officer | – |
| Eric Francois | Director | – |
| Shami Patel | Director | 1,120,254 |
| Lindsey Rolfe | Director | – |
| Michael Byrnes | Director | – |
| Kathleen Laporte | Director | 989,325 |
| Brian G. Atwood | Director | 516,784 |
Employees
Headcount reported in annual reports
“As of December 31, 2025, we had eight full-time employees, including two executive officers and six employees conducting Research and Development.”
Corporate history
Events identified from SEC filings